MBIO Stock Price, Chart, Stats & News
Mustang Bio, Inc. (MBIO) does not currently pay a dividend.
MBIO chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -10.92% |
ROE | -29.78% |
D/E | – |
Interest coverage ratio | – |
MBIO valuation
P/E | – |
P/S | – |
P/B | 0.55x |
P/CF | -1.00x |
P/FCF | -1.04x |
P/OCF | -1.00x |
PEG | -0.04x |
EV multiple | -10.65x |
About
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital.
Similar securities
Based on sector and market capitalization
